Phil Donenberg

Phil Donenberg joined the IR2Dx Board of Directors in April 2012. Mr. Donenberg is Senior Vice President, Chief Financial Officer of AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological diseases. He previously served as Chief Financial Officer of RestorGenex, and BioSante Pharmaceuticals, Inc.’s (NASDAQ:BPAX) Senior Vice President of Finance from 2010 until June 2013, and Chief Financial Officer and Secretary from 1998 until June 2013, when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. BioSante was a specialty pharmaceutical company focused on developing products for women’s and men’s health and oncology. From 1995 to 1998, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of AbbVie Inc.), a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. Prior to Unimed Pharmaceuticals, Inc., he held similar positions with several other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. and Xtramedics, Inc. For the past seven years, he has been a frequent guest lecturer for various MBA and Undergraduate College of Business classes at the University of Illinois Champaign-Urbana and Lake Forest Graduate School of Management.

Mr. Donenberg earned a B.S. in Accountancy from the University of Illinois Champaign-Urbana College of Business, and is a Certified Public Accountant.